Sarve

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sarve

Sarve is a widely recognized prescription-only medication primarily used in the management of high blood pressure, known as hypertension. It is classified as an Angiotensin II Receptor Blocker (ARB), a class of cardiovascular drugs that specifically targets the body's natural blood pressure regulation system.


Quick Facts

Property Description
Active ingredient Losartan Potassium
Form Film-coated tablets
Pharmacological class Angiotensin II Receptor Blocker (ARB)
General purpose Lowering and controlling high blood pressure
Origin Synthetic (non-peptide molecule)

What Type of Medicine is Sarve (Losartan)?

Sarve is an Angiotensin II Receptor Blocker (ARB), which is the official pharmacological class for its active ingredient, Losartan Potassium. ARBs function by interfering with the Renin-Angiotensin-Aldosterone System (RAAS). Losartan acts as a competitive antagonist, blocking the action of the potent hormone Angiotensin II at the AT1 receptor site. This selective blockade, clinically recognized for its efficacy, is crucial for preventing the signaling that leads to the constriction of blood vessels.

Losartan is a non-peptide, chemically synthesized molecule used for the oral route of administration. It is an orally active agent approved for the general purpose of reducing the risk associated with elevated blood pressure.

Composition and Pharmaceutical Form

The medication is a single-ingredient product, containing Losartan administered as the monopotassium salt, and is dispensed as film-coated tablets. Losartan itself is considered a prodrug, a compound that requires internal processing to achieve its full therapeutic effect. Its primary and most potent action is mediated by its active metabolite, designated as EXP3174 (or E3174).

General Purpose: Why is Losartan Used?

The fundamental purpose of Losartan's mechanism is to promote blood vessel relaxation and maintain vascular tone. By blocking Angiotensin II, the drug mitigates its vasoconstricting effects, allowing blood vessels to widen and reducing the overall resistance to blood flow. This physiological effect makes the medication suitable for achieving and maintaining sustained control over hypertension, thereby reducing the workload on the heart. The drug’s action helps reduce resistance to blood circulation throughout the body.

Regulatory References

  1. Losartan (MedlinePlus)

What side effects are possible with Sarve?

Possible Side Effects and Safety Information

The official safety profile for Sarve (Losartan Potassium) is structured by the frequency of documented adverse reactions and specific population constraints, consistent with regulatory standards.

Frequency-Classified Adverse Reactions

Side effects are categorized based on incidence rates observed in clinical trials and post-marketing experience, utilizing the following regulatory framework:

Frequency Category Representative Adverse Reactions
Common (1/100 to <1/10) Dizziness, Upper respiratory infection, Back pain, Nasal congestion
Uncommon (1/1,000 to <1/100) Fatigue/Asthenia, Insomnia, Palpitations, Diarrhea, Rash
Rare (1/10,000 to <1/1,000) Angioedema, Hypersensitivity reactions

Adverse reactions are also classified by the body systems they affect, including the Nervous System (e.g., Headache), Vascular System (e.g., Hypotension), Gastrointestinal System, and Renal System (e.g., Renal impairment).

Serious Adverse Reactions and Restrictions

Specific serious adverse reactions are highlighted in regulatory labeling. Angioedema, a rare but severe swelling of the face, lips, or throat, is documented. A major safety restriction involves Fetal Toxicity: the medicine is contraindicated during the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus. Patients with severe hepatic impairment also have an explicit contraindication, and close monitoring of renal function and serum potassium is advised for susceptible populations. The risk of symptomatic hypotension is noted as potentially occurring following the first dose or a dose increase in volume-depleted patients.

Overdose and Emergency Response

The official regulatory documentation on Sarve (Losartan Potassium) overdose focuses on the documented physiological manifestations and the required immediate emergency response. An acute overdose may result in an exaggerated extension of the drug's intended action, leading primarily to significant hypotension (low blood pressure).

Other documented clinical signs include changes in heart rhythm, specifically tachycardia (fast heart rate) or, less commonly, bradycardia (slow heart rate). Because of the low blood pressure, individuals may also experience dizziness. These presentations can escalate to serious or life-threatening cardiovascular outcomes, including profound hypotension and the potential for vascular shock.

Regulatory authorities mandate that individuals must seek immediate medical attention for any suspected overdose event. Emergency services should be contacted immediately if symptoms are severe, particularly if they indicate profound hypotension.

Management of a Sarve overdose is strictly symptomatic and supportive, as official labeling confirms that no specific antidote is known. The supportive measures documented in regulatory information include placing the patient in a supine position and, if ingestion was recent, procedures such as gastric lavage or administration of activated charcoal may be considered by medical professionals. Close clinical observation and frequent monitoring of vital signs are required.

Therapeutic Uses of Sarve

What Sarve Treats: Main Uses and Benefits

Sarve (Losartan) is a commonly used medication that assists with the management of chronic conditions, focusing on long-term risk reduction and supports vital organs from the damaging effects of persistent high blood pressure. Its primary application is the management of high blood pressure (hypertension).

The medication is generally applied across conditions presenting with systemic or localized discomfort, supporting the management of symptoms related to physiological strain. Specifically, Sarve is used to address the high-risk state of patients with hypertension to help in reducing the likelihood of major cardiovascular events, including stroke and heart attack. It is also utilized for the specialized management of diabetic nephropathy (kidney disease) in patients with Type 2 diabetes and, in certain cases, as supportive therapy for Heart Failure when other options are appropriate.

This comprehensive approach provides support that helps ease the overall symptom load associated with chronic high blood pressure, assisting patients with maintaining functional stability and supporting general well-being during symptomatic phases.


Quick Facts: Therapeutic Focus

Property Description
Primary Therapeutic Domain Management of systemic high blood pressure (hypertension)
Secondary Focus Assists with reducing the likelihood of stroke and heart attack
Specialized Use Relevant for managing symptoms linked to organ-specific functional stress, particularly in diabetic nephropathy

Regulatory References

  1. National Institutes of Health (NIH) official labeling for Losartan Potassium

Eligibility and Restrictions for Use

Who Can and Cannot Use Sarve?

Sarve (Losartan) is restricted to specific patient populations as defined by regulatory authorities. Use is officially approved for adults and for the treatment of hypertension only in children aged 6 to 18 years. The medicine is not recommended for children under six years old, as safety and efficacy have not been established in this younger age group.


Absolute Contraindications

Sarve must not be used by several groups as explicitly stated in the regulatory label:

  • Women who are pregnant, particularly during the second and third trimesters, and use is not recommended during the first trimester.
  • Patients with a known hypersensitivity to Losartan, or a history of angioedema related to previous Angiotensin Receptor Blocker (ARB) or ACE inhibitor therapy.
  • Patients diagnosed with severe hepatic impairment.
  • Patients with diabetes or renal impairment (GFR < 60) who are also taking aliskiren.

Conditional Use and Limitations

Use is generally not recommended for patients with primary hyperaldosteronism or bilateral renal artery stenosis. A lower starting dose is specified in the label for patients with mild-to-moderate liver impairment or those who are volume-depleted. Furthermore, the drug is not recommended for use while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Sarve (Losartan Potassium) is formally documented by regulatory authorities, outlining specific combinations and substances that affect its action or the risk profile. The co-administration of Losartan with Aliskiren is officially contraindicated in patients with established diabetes mellitus or with moderate to severe renal impairment, due to a heightened risk of hypotension, hyperkalemia, and kidney function decline. Dual blockade of the Renin-Angiotensin System (RAS) with ACE inhibitors is also generally not recommended.

Pharmacodynamic and Metabolic Interactions

Interactions that affect the body's enzyme system are formally noted. Fluconazole, a CYP2C9 inhibitor, increases the systemic exposure of Losartan while decreasing the exposure of its active metabolite, EXP3174. Conversely, CYP inducers such as Rifampin and Phenobarbital are documented to reduce the exposure of both Losartan and its active metabolite.

Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the blood pressure-lowering effect of Losartan and increases the documented risk of kidney function deterioration. The use of potassium-sparing diuretics or potassium supplements carries a substantial risk of hyperkalemia (elevated serum potassium), an additive pharmacodynamic effect. Furthermore, Losartan co-administration is documented to increase serum concentrations of Lithium, potentially leading to toxicity.

Mechanism of Action

Targeted Blockade of Immune Messaging

Sarve's core mechanism involves the targeted blockade of Interleukin-6 (IL-6) receptors, acting as a receptor antagonist to prevent the IL-6 messenger molecule from activating its cellular target. This action initiates the drug's effect by disrupting a key signal transmission process between immune cells.


Modulating the Downstream Signaling Pathway

The physical blockade of the IL-6 receptor interrupts the subsequent JAK-STAT signaling cascade inside the cell. By suppressing this specific signaling pathway, Sarve limits the genetic instructions that influence the synthesis of multiple inflammatory mediators.


Systemic Modulation of Inflammatory Activity

The consequence of interrupting this signaling pathway is a decrease in the activity of the systemic inflammatory response system throughout the body. This mechanistic domain results in a demonstrable decrease in the levels of key inflammatory markers and acute-phase proteins, contributing to the modulation of physiological responsiveness.

Dosage and Administration Information

How to use Sarve: Official Administration Guidelines

Sarve (Losartan) is administered strictly via the oral route as film-coated tablets in strengths including 25 mg, 50 mg, and 100 mg. The medication is generally taken once daily and may be consumed with or without food, offering flexibility in the daily routine. Tablets should be swallowed whole with water, and if a dose is missed, the patient should simply take the next scheduled dose at the regular time, without doubling the dose.

Standard Dosing and Titration

The usual starting dose for most adults is 50 mg once daily. This regimen is maintained for several weeks, as the maximal therapeutic effect is typically attained after three to six weeks of treatment. Based on the response observed during this period, the dose may be adjusted (titrated) upward to a maximum of 100 mg once daily for the primary indications. The tablets are typically scored, which allows for division to achieve precise dose adjustments.

Administration in Specific Populations

Dose adjustments are required for certain populations. For patients with volume depletion (such as those taking high-dose diuretics) or those with mild-to-moderate hepatic impairment, a lower initial dose of 25 mg once daily is necessary. Conversely, for most adults with renal impairment or those undergoing dialysis, no initial dose adjustment is needed. Pediatric patients (aged 6–16) with hypertension begin treatment with a calculated dose of 0.7 mg/kg once daily, up to an initial maximum of 50 mg.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sarve


Evidence for Use in Managing Systemic High Blood Pressure (Hypertension)

Research examining Losartan in high blood pressure (hypertension) has largely relied on large-scale Randomized Controlled Trials (RCTs). These trials compared the measured changes from different treatments under controlled conditions. Studies primarily monitored outcomes related to physiological strain by measuring changes in Systolic and Diastolic Blood Pressure (BP). Studies reported reductions in BP measurements in the observed adult populations. Furthermore, in specific high-risk groups—such as those with evidence of Left Ventricular Hypertrophy (LVH)—studies described patterns suggesting a difference in the number of stroke events observed when compared to certain older treatment approaches.

Evidence for Use in Diabetic Kidney Disease (Diabetic Nephropathy)

The research exploring Sarve for kidney disease linked to Type 2 diabetes involved large, controlled, long-term clinical trials. These studies focused on patients with established diabetic nephropathy, a condition associated with functional imbalance and persistent proteinuria. The research monitored physiological strain by examining changes in the rate of kidney function decline and specific composite renal endpoints. Trials consistently monitored the difference in the rate of progression to the composite renal endpoint, which included severe outcomes like the need for dialysis or End-Stage Renal Disease (ESRD), when compared to the placebo group. Research also highlights a decrease in the levels of proteinuria (albuminuria) in the observed patient populations.

Evidence for Use as Supportive Therapy in Heart Failure

Sarve has been studied for use in patients with Heart Failure (HF) through Randomized Controlled Trials and subsequent Meta-analyses. Research explored this use primarily in patients with reduced Left Ventricular Ejection Fraction (LVEF). The main outcomes monitored included the frequency of hospitalization, changes in heart function, and all-cause mortality. Studies conducted during periods of increased symptom activity reported observations related to changes in hemodynamic parameters in the short term. However, the outcomes analyzing Losartan treatment in relation to long-term mortality compared with other long-established first-line heart failure medications have shown variability across different study designs.


Research Gaps and Areas of Uncertainty

The body of evidence contains several research gaps and areas of uncertainty. One key area is the limited information for long-term outcomes beyond the five-year scope of the longest published trials. Comparative evidence is lacking for many head-to-head comparisons against all newer classes of blood pressure medications. Furthermore, subgroup findings are uncertain in several contexts: there is insufficient data to firmly characterize the use of Sarve in patients with early or mild diabetic kidney disease; and data for certain high-risk groups outside of those specifically studied remain insufficient. Overall, evidence highlights what is known, and what is still uncertain, emphasizing that research provides context but not individual predictions.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline: Hypertension in adults: diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Sarve (FAQ)


Q: What are the possible long-term side effects if I take Sarve for an extended period?

Official safety documents list a wide range of side effects observed in clinical trials, categorized by how often they occur. These reports cover both short-term and extended use. Official information advises that regular monitoring of kidney function and potassium levels is necessary for certain patient groups, especially those on long-term therapy, as changes in these measures have been documented.


Q: Why do some people report a specific symptom, like an upset stomach, when using Sarve?

Official adverse reaction reports indicate that some patients taking Sarve have experienced gastrointestinal side effects. These can include diarrhea and abdominal pain, which are listed as common in the product information. Nausea and vomiting have also been reported.


Q: Can Sarve be taken at the same time as common supplements like vitamins or fish oil?

Official documents advise that patients inform their healthcare provider about all medicines, vitamins, and herbal supplements being taken. This is due to the potential for interactions, as specific general statements regarding common vitamins or fish oil are not included in the standard drug label.


Q: Are there any recent scientific studies or clinical trials on the effectiveness of Sarve?

The efficacy of Sarve is established based on key large-scale clinical trials summarized in regulatory documents, including those used for its initial approval. While the information details the results of these trials, it also notes that long-term outcomes beyond five years are limited, providing context on the latest available data.


Q: What does the research say about Sarve's mechanism of action?

Research cited in regulatory documents confirms that Sarve works as an Angiotensin II Receptor Blocker (ARB). This means it selectively blocks the binding of a potent hormone called Angiotensin II to its specific receptor ( AT1) in the body, which prevents blood vessels from constricting.


Q: Has Sarve been approved by major health regulatory bodies in my region?

Sarve (Losartan) is a widely used medication and is approved by major governmental health regulatory bodies around the world, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for its labeled uses.


Q: How long does it typically take for a person to start noticing the benefits of Sarve?

Regulatory documents state that the antihypertensive effect is substantially present within one week of starting therapy. However, official product information indicates that the full or maximal therapeutic benefit may take longer to achieve, typically being reached after three to six weeks of consistent treatment.


Q: If I stop taking Sarve, do the effects wear off immediately?

The drug and its active form have known half-lives (the time it takes for the concentration to reduce by half) listed in regulatory documents. This indicates that the medicine is cleared from the system over time rather than instantaneously.


Q: Can Sarve affect blood pressure or blood sugar levels?

Sarve is intended to lower blood pressure, but patients can potentially experience symptomatic hypotension (excessively low blood pressure), especially when starting treatment. Furthermore, official adverse reaction reports list hypoglycemia (low blood sugar) as an uncommon side effect in certain patient groups, such as those with diabetic kidney disease.


Q: Is it possible for Sarve to cause a skin rash or itching?

Yes, regulatory documents list rash as an uncommon side effect. Additionally, other reactions affecting the skin, such as pruritus (itching) and urticaria (hives), have also been documented in post-marketing reports.


Q: Does Sarve interact with alcohol?

Official information notes that both Sarve and alcohol can contribute to lowered blood pressure. This combination may increase the risk of side effects such as dizziness, light-headedness, or fainting.


Q: Does Sarve have any known psychiatric or mood-related side effects?

Regulatory documents list side effects categorized under psychiatric disorders or nervous system effects. These reports include insomnia (difficulty sleeping) as a common side effect and other rare effects, such as confusion or depression, have been reported in post-marketing surveillance.


Q: What kind of monitoring is usually needed when taking Sarve for a long time?

Official safety precautions indicate that regular monitoring of renal function (kidney function) and serum potassium levels is advised, especially for susceptible populations. This monitoring helps manage potential risks associated with long-term use.


Q: Is it true that Sarve might increase sensitivity to sunlight?

Official post-marketing experience reports have included photosensitivity (increased sensitivity to the sun) as an adverse reaction with an unknown frequency. Patients should be mindful of sun exposure while using Sarve.


Q: Does Sarve contain any common allergens, like gluten or lactose?

Regulatory labels list the inactive ingredients, and Sarve tablets include lactose hydrous (a form of milk sugar). Patients with known sensitivities to inactive ingredients, such as lactose, should seek guidance from a healthcare professional.


Q: Why are people often confused about the proper timing for taking Sarve (e.g., with or without food)?

The official administration guidelines allow the medication to be taken with or without food because the long-term effectiveness is similar in both conditions. Although food can slightly slow the drug's absorption rate, the overall benefit is not significantly affected.


Q: Why do some forums suggest taking Sarve on an empty stomach?

Regulatory data indicates that taking the medicine on an empty stomach results in the highest and quickest peak concentration ( C max) of the drug. This effect on absorption rate may influence individual preference, even though the long-term effectiveness is similar regardless of food.


Q: Can Sarve cause changes in sleep patterns?

Official regulatory documents list insomnia (difficulty falling or staying asleep) and other sleep disorders as uncommon adverse reactions. These effects are reported by some patients during treatment.


Q: What is the typical duration of treatment with Sarve?

Sarve is indicated for the treatment of chronic conditions, such as high blood pressure and diabetic kidney disease. Because of this, treatment typically requires long-term or often life-long therapy to effectively control blood pressure and manage the progression of these diseases.


Q: Can Sarve be used for conditions other than its primary indication, as sometimes mentioned online?

Sarve is only officially approved and indicated by regulatory bodies for the management of hypertension, for the reduction of stroke risk in patients with specific cardiac issues, and for treating diabetic nephropathy in patients with Type 2 diabetes. Use of Sarve for any other condition falls outside of the officially approved and indicated uses listed in the regulatory labeling.

How should Sarve be stored and disposed of?

How to Store and Dispose of Sarve (Losartan Potassium Tablets)

The storage and disposal of Sarve must strictly adhere to the conditions documented in official regulatory labeling to ensure product quality.

Storage Requirements

Sarve tablets must be stored at controlled room temperature, typically maintained between 20°C and 25°C. The medication must be kept in its original container and the cap must be tightly closed to protect it from excessive heat, light, and moisture. The product should not be stored near areas with high humidity, such as a bathroom.

Child Safety and Disposal

All medication must be stored out of the reach and sight of children. Do not keep outdated or unused Sarve. For disposal, unused or expired tablets should not be discarded in household waste or flushed down the toilet. Patients must consult a pharmacist or local waste management facility for instructions on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sarve found in:

A-Z Index: